Literature DB >> 12671447

Respiratory syncytial virus and other respiratory viruses.

Robert C Welliver1.   

Abstract

Respiratory syncytial virus (RSV), a nonsegmented, single stranded RNA virus, infects one-half of all infants within the first year of life. RSV possesses pathogenetic qualities that may be attributed to the interplay of viral and host-specific factors including virus strains of different virulence, size of the inoculum, family history of asthma or airway hyperreactivity and immunologic anomalies of the host. Inflammatory cell recruitment and activation occur in response to RSV infection of epithelial cells. Epithelial cells initiate the inflammatory response to RSV by elaborating a wide variety of cytokines and chemokines that trigger further inflammatory responses. Helper T lymphocytes mediate the relative balance of cytokine production and also secrete a variety of antiviral and proinflammatory interleukins. Elevated levels of macrophage-inflammatory protein-1-alpha, an attractant of eosinophils, and monocyte chemotactic protein-1 parallel severe forms of bronchiolitis. Macrophage-inflammatory protein-1-alpha and monocyte chemotactic protein-1 levels also are inversely related to oxygen saturation, suggesting that severity of RSV disease may be linked to chemokine release. Children known to be eosinophilic during an episode of bronchiolitis appear more prone to wheeze at an older age. Influenza, parainfluenza and metapneumoviruses share major epidemiologic risk factors for lower respiratory tract infection similar to those of RSV. Like RSV some of these viruses may also promote an exaggerated lymphocyte-proliferative response, and subjects infected with parainfluenza viruses produce elevated levels of virus-specific IgE. Preliminary evidence suggests that severe RSV and influenza viral infections are mediated via chemokine up-regulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12671447     DOI: 10.1097/01.inf.0000053880.92496.db

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  38 in total

Review 1.  Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

2.  Association of IL-13 in respiratory syncytial virus-induced pulmonary disease: still a promising target.

Authors:  Sumanta Mukherjee; Nicholas W Lukacs
Journal:  Expert Rev Anti Infect Ther       Date:  2010-06       Impact factor: 5.091

3.  Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus.

Authors:  Nicholas W Lukacs; Martin L Moore; Brian D Rudd; Aaron A Berlin; Robert D Collins; Sandra J Olson; Samuel B Ho; R Stokes Peebles
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

Review 4.  Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.

Authors:  Kerry M Empey; R Stokes Peebles; Jay K Kolls
Journal:  Clin Infect Dis       Date:  2010-05-01       Impact factor: 9.079

5.  Respiratory virus-induced regulation of asthma-like responses in mice depends upon CD8 T cells and interferon-gamma production.

Authors:  Joost J Smit; Louis Boon; Nicholas W Lukacs
Journal:  Am J Pathol       Date:  2007-11-08       Impact factor: 4.307

Review 6.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

7.  RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.

Authors:  Wenliang Zhang; Ralph A Tripp
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

8.  CXCL10/CXCR3-mediated responses promote immunity to respiratory syncytial virus infection by augmenting dendritic cell and CD8(+) T cell efficacy.

Authors:  Dennis M Lindell; Thomas E Lane; Nicholas W Lukacs
Journal:  Eur J Immunol       Date:  2008-08       Impact factor: 5.532

9.  Neonatal immunization with respiratory syncytial virus glycoprotein fragment induces protective immunity in the presence of maternal antibodies in mice.

Authors:  Youran Noh; Byoung-Shik Shim; In Su Cheon; Semi Rho; Hee Joo Kim; Youngjoo Choi; Chang-Yuil Kang; Jun Chang; Man Ki Song; Jae-Ouk Kim
Journal:  Viral Immunol       Date:  2013-07-19       Impact factor: 2.257

10.  Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.

Authors:  Matthew B Elliott; Karin S Pryharski; Qingzhong Yu; L A Boutilier; N Campeol; K Melville; Todd S Laughlin; C K Gupta; Robert A Lerch; Valerie B Randolph; Natisha A LaPierre; Kristen M Heers Dack; Gerald E Hancock
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.